• Gilead Sciences Inc GILD.OQ reported quarterly adjusted earnings of $1.90​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $1.72. The mean expectation of twenty four analysts for the quarter was for earnings of $1.70 per share. Wall Street expected results to range from $1.57 to $1.83 per share.

• Revenue rose 6.4% to $7.57 billion from a year ago; analysts expected $7.14 billion.

• Gilead Sciences Inc's reported EPS for the quarter was $1.42​.

• The company reported quarterly net income of $1.78 billion.

• Gilead Sciences Inc shares had risen by 3.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 13 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Gilead Sciences Inc is $99.00

This summary was machine generated from LSEG data February 11 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)